Evaluation of chimerism following allogeneic transplantation has been performed traditionally focusing on two cellular compartments, namely lymphoid and myeloid. However, none has been described so far to evaluate platelet chimerism. In order to achieve full chimerism in all three cellular compartments, we prospectively obtained 138 samples of peripheral blood in 55 patients at different post transplant periods following allogeneic hematopoietic transplantation. Evaluation of chimerism was performed utilizing tests of variable number of tandem repeat (VNTR) and sex determination by quantitative polymerase chain reaction (PCR). Tests for platelet chimerism using platelet-rich plasma were simultaneously analyzed with samples for T-cell lymphoid and myeloid compartments. Complete donor chimerism was noted in 49 of 55 patients (89%), while the remaining six have split chimerism ranging from 34 to 98%. There is significant difference (P ¼ 0.0004) between the percentages of donor DNA in all three cellular compartments comparing the means7s.e.m. (myeloid 95.6070.9, T-cell lymphocytes 87.671.9, and the platelets 90.871.5); however, comparison between the medians is not statistically significant. This study represents an additional step towards achieving full chimerism and the observation may help reduce the number of unnecessary platelet transfusions once chimerism is noted in that cellular compartment.
cell transplant; PCR Allogeneic hematopoietic stem cell transplantation is currently used in treating a number of hematologic and oncologic disorders. Therefore, the evaluation of early engraftment or the degree of donor chimerism is very important in the follow-up of these patients. There is no consistent or uniform method by which most centers evaluate donor chimerism. The recent workshop sponsored by the International Bone Marrow Transplant Registry and National Marrow Donor Program recommended that a complete or full chimerism analysis be performed in all allogeneic lymphohematopoietic transplantation. 1 Traditionally, chimerism analysis is performed in whole blood [2] [3] [4] or by utilizing two-cell lineage: T-lymphocytes and myelocytes. [5] [6] [7] These lineage-specific chimerism studies are currently the method of choice in the setting of nonmyeloablative therapy and reduced intensity conditioning regimens. [6] [7] [8] [9] [10] This study was conducted in an attempt to establish a reasonably uniform protocol, whereby our variable number of tandem repeat (VNTR) studies (utilizing the usual T-lymphocytes and myeloid) are extended to include platelet chimerism and the results are analyzed in comparison with each compartment for engraftment.
Materials and methods
A total of 138 samples of peripheral blood were obtained from 55 pediatric patients before and after transplantation between 1999 and March 2002. The patients ranged in age between 1 and 21 years. Clinical diagnoses included acute lymphoblastic leukemia (n ¼ 23), acute nonlymphoblastic leukemia (ANLL, n ¼ 13), hyper-IgM (n ¼ 2), lymphoma (n ¼ 2), thalassemia (n ¼ 1), sickle cell anemia (n ¼ 2), osteopetrosis (n ¼ 1), Duncan's syndrome (n ¼ 1), Sandhoff's disease (n ¼ 1), familial hemophagocytic syndrome (n ¼ 2), chronic myelogenous leukemia (n ¼ 2), Hurler's syndrome (n ¼ 2) and myelodysplastic syndrome (n ¼ 3).
Sample preparation
Samples were obtained when an initial cell count reached an absolute neutrophil count 4500 in 2 consecutive days post transplant. They were collected in EDTA-anticoagulated tubes and soft spun at 1000 rpm for 30 min. Plateletrich plasma was separated and the remaining samples were then divided into three separate aliquots. From these three aliquots, cells were prepared to obtain total cells, CD3-positive lymphoid cells and CD33-positive myeloid cells. From the plasma, platelet purity was determined by staining cells with anti-CD61 and anti-CD45 antibodies. After each cell lineage separation, the purity of the samples between lymphoid (CD3) and myeloid (CD33) (Stem Cell Technologies), and platelets (CD61) was evaluated by flow cytometry (FACSort Becton Dickenson) (Figure 1 ). Each sample was prepared for DNA extraction using QIAamp DNA blood mini kit (Cal # Valencia, Ca, USA) according to the attached protocol. DNA screening was first carried out in the pretransplant samples of donor/recipient pair using amplification of at least five primers of VNTR loci (Table 1) to find the most informative locus. The informative gene was then used to follow subsequent post transplant samples for study. Platelet chimerism was initiated when no platelet transfusion had been given for at least 10-14 days.
Each reaction was performed in a volume of 20 ml containing 0.8 ml of 25-mm MgC1 2 solution, 2.0 of 10 Â polymerase chain reaction (PCR) buffer 11, 1.6 ml and 10 mm each of dNTPs (PE Applied Biosystem, Foster City, CA, USA) and 1 ml of 20 pmol of each primer and 100 ng of DNA. A 100-bp DNA ladder (Cat. no. 15628-019; Life Technologies, Inc.) was used. This ladder consists of fragments between 100 and 1500 bp in multiples of 100 bp and an additional fragment at 2072 bp. All reactions were carried out by the same operator.
Analysis of PCR products
After 30 cycles of amplification, samples were run on a 1.5% agarose gel (Cat. no. A-0169, Sigma, St Louis, MO, USA) and visualized by SYBR Green I gel stain (Molecular Probes, Eugene, OR, USA). Gels were analyzed using Alpha Imager 200 Documentation and Analysis System (Alpha Innotech Corp. San Leandro, CA, USA). The degree of chimerism was assessed by determining the ratio of visible band from the donor and recipient using the following formula:
Area of donor band Area of donor band þ Area of recipient band Â100%
If a common band was shared between the donor and recipient, only the informative band was included in the calculation. For flow cytometry, 50 ml of plasma-rich platelet was stained with CD61 and CD45 for platelet purity ( Figure 1 ) and postisolated cells for specific cell lineage with CD33 and CD3.
Statistics
Linear regression analysis was performed using Regression Wizard of Sigma Plot 5.0 (GraphPad software, San Diego Platelet chimerism by PCR utilizing VNTRs CA, USA). The regression coefficients were calculated and statistical significance was determined by the F-test.
Results
Complete chimerism (98-100% donor cells) was found in all three cellular compartments in 49 out of 55 patients (89%) at day 100 of post transplant (see representative case Figure 2 ), while the remaining six (11%) have split chimerism ranging from 34 to 98% (see representative case Figure 3 ). Two patients had persistent mixed chimerism up to 3 months post transplant. Three patients continued to receive donor lymphocyte infusion (DLI) and are currently being monitored for donor/recipient chimerism. A comparison of the three compartments shows a statistically significant difference of the means between the three compartments (P ¼ 0.0004), but the medians are similar (Table 2) .
Discussion
In our laboratory, we routinely utilize VNTR analysis by PCR to monitor engraftment and had previously reported that incomplete chimerism correlated with clinical relapse in pediatric leukemias. 2 Developing an optimal method for detecting full chimerism may enhance our ability to identify patients at risk for early relapse. 3, 4 Chimerism assay allows for differentiation between recipient and host cells, and is used as an alternative method to identify minimal residual disease, especially in those cases without specific cytogenetic markers. 2, 8, 9 Occasionally, it is used in combination with other tests for documenting engraftment. 5, 10 Clearly, any method leading to early detection is crucial, since it is now possible to prevent increasing mixed chimerism at an early stage with DLI . 11 A recent report also supported the notion that DLI administration to mixed chimera in mice dramatically improved leukemia-free survival. 12 By extending our evaluation to include platelet chimerism, we have found that 89% of our patients were able to achieve full donor chimerism in all three cell lineages by day 100 of post transplant. The presence of residual host cells during the first 100 days post transplant is not an uncommon event as had been previously reported by us, 2 as well as by Gaiger et al.
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In our series, the majority of our patients eventually became fully chimeric; however, we have two patients who continued to have mixed chimerism up to 2 years post transplant. Since these patients did not have malignant diseases and particularly since the amount of donor chimerism was sufficient to correct their enzymatic defect, DLI infusion was not considered necessary. The general trend, at present, is to maintain donor engraftment of up to 10% or even less, as long as there is enough to provide functional reversal of the underlying disorder. In all likelihood, since we are using a less intense conditioning regimen for treating severe aplastic anemia, the presence of mixed chimerism is clinically irrelevant, provided hematopoiesis could be sustained. 14, 15 In many other conditions such as organ transplantation, congenital disorder of metabolism and immune therapy of solid tumors, establishing a mixed chimerism state may be preferable to full donor chimerisms for the immunologic benefits. Although this is controversial, as others strive to achieve complete donor chimera, long-term mixed chimerism is a frequent consequence of allogeneic transplantation in a nonmalignant condition. 1 Two other patients in our series: one with CML and one with ANLL also did not achieve donor chimerism and required several infusions of DLI before eventually becoming fully chimeric. DLI is the key to the success of allogeneic transplantation if given at a critical point during the post transplant period. Compartmental engraftment is probably a more important issue in cases of persistent mixed chimerism in nonmalignant conditions. As more and more patients with nonmalignant disorders received allogeneic transplantation, the importance of evaluating chimerism in all cell lineages would become more apparent. It has been shown that the assessment of mixed chimerism in myeloid lineage predicts relapse in myeloid and not lymphoid malignancies. Likewise, assessment of T-cell chimerism provides important prognostic information including GVHD, graft rejection and GVT effects in patients with solid tumors. Currently, there is no optimal methodology to assess chimerism in solid tumor transplantation, since neither myeloid nor T-cell chimerism have shown any significant differences in controlling tumor growth. 1 At the time of this report, the significance of our result, specifically discrepant platelet chimerism as compared to two other cellular compartments, is uncertain. Certainly one could postulate that in such patients, early complete donor chimerism in platelet compartment denotes recovery and, therefore, requires less platelet transfusion. We have previously shown that early platelet recovery can be assessed with certainty 16 and would likely result in the need for less platelet transfusion in the future. Information derived from this study, however, shows that there is a subset of patients with complete chimerism in the lymphoid and myeloid compartments, but show split chimerism in their platelets; some for up to 2 years post transplant. This subset of patients should be followed in order to observe the long-term effect of mixed platelet chimerism on patient recovery.
